Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 28 May 2022 - 3 Jun 2022
STUDY TYPE:Human Studies, Pharmacology/Drug Development
DATE PUBLISHED: 2022 May 28
JOURNAL:Lancet
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35644154?dopt=Abstract
Volume:399
ISSUE:10340
Editor's Pick
Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.